Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms

Introduction: Physicians have largely studied the cutaneous involvement of coronavirus disease 2019 (COVID-19), but only few reports have focused on telogen effluvium (TE) as a possible sequela of COVID-19. We assessed 14 cases of hair loss occurring after SARS-CoV-2 infection using trichoscopy and trichogram to investigate patterns related to COVID-19. Furthermore, we discussed possible mechanisms involved in COVID-19 TE. Case Presentation: Fourteen individuals were referred to our post-COVID-19 dermatology office complaining acute hair loss after SARS-CoV-2 infection. Clinical evaluation included pull test, trichoscopy, and trichogram. COVID-19 TE occurred after a median of 2 months (range 1–3 months) following SARS-CoV-2 infection. The median duration of hair loss was 5 months (range 1–6 months). Trichoscopy showed variable but typical TE patterns. Trichogram showed different telogen/anagen ratio depending on the interval between onset of hair loss and trichological visit. Discussion/Conclusion: Our cases showed TE between 1 and 3 months after the onset of SARS-CoV-2 infection, thus earlier than classic TE. Trichoscopic features and trichogram showed no variations from classic TE. Different pathogenetic mechanisms including pro-inflammatory cytokines and direct viral damage on the hair follicle can be hypothesized; further studies on a larger sample are needed to better understand this condition.

[1]  R. Trüeb,et al.  What can the hair tell us about COVID‐19? , 2020, Experimental dermatology.

[2]  B. McLellan,et al.  Telogen effluvium: a sequela of COVID‐19 , 2020, International journal of dermatology.

[3]  A. Offidani,et al.  Telogen effluvium related to post severe Sars‐Cov‐2 infection: Clinical aspects and our management experience , 2020, Dermatologic therapy.

[4]  Daniel J. Gould,et al.  Cutaneous Manifestations of COVID-19: An Evidence-Based Review , 2020, American Journal of Clinical Dermatology.

[5]  D. Fernández-Nieto,et al.  Acute telogen effluvium associated with SARS-CoV-2 infection. , 2020, Australian journal of general practice.

[6]  K. Karthik,et al.  Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19 , 2020, Human vaccines & immunotherapeutics.

[7]  C. Colak,et al.  Evaluation of the effects of COVID‐19 pandemic on hair diseases through a web‐based questionnaire , 2020, Dermatologic therapy.

[8]  H. Ulrich,et al.  Dengue Fever, COVID‐19 (SARS‐CoV‐2), and Antibody‐Dependent Enhancement (ADE): A Perspective , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[9]  N. Rivetti,et al.  Management of telogen effluvium during the COVID‐19 emergency: Psychological implications , 2020, Dermatologic therapy.

[10]  Tsung-Hsien Chang,et al.  Dengue Virus Infects Primary Human Hair Follicle Dermal Papilla Cells , 2018, Front. Cell. Infect. Microbiol..

[11]  A. Wróbel,et al.  Interleukin-4 induces apoptosis in cultured human follicular keratinocytes, but not in dermal papilla cells. , 2002, European journal of dermatology : EJD.

[12]  C. Harmon,et al.  Interleukin-1beta is differentially expressed by human dermal papilla cells in response to PKC activation and is a potent inhibitor of human hair follicle growth in organ culture. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[13]  A. Tosti,et al.  Telogen effluvium due to recombinant interferon alpha-2b. , 1992, Dermatology.

[14]  F. Malkinson PATHOLOGIC DYNAMICS OF HUMAN HAIR LOSS , 1961 .

[15]  A. Kligman Pathologic dynamics of human hair loss. I. Telogen effuvium. , 1961, Archives of dermatology.